These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 15109534

  • 21. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V.
    Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
    [Abstract] [Full Text] [Related]

  • 22. Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
    Leoni F, Ciolli S, Nozzoli C, Santini V, Fanci R, Rossi Ferrini P.
    Haematologica; 2001 Jan; 86(1):104. PubMed ID: 11146581
    [No Abstract] [Full Text] [Related]

  • 23. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E.
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [Abstract] [Full Text] [Related]

  • 24. Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
    Kim H, Park JH, Lee JH, Lee JH, Joo YD, Lee WS, Bae SH, Mo Ryoo H, Lee KH, Cooperative Study Group A for Hematology.
    Am J Hematol; 2009 Mar; 84(3):161-6. PubMed ID: 19195034
    [Abstract] [Full Text] [Related]

  • 25. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, Dmoszynska A, Skotnicki A, Nowak K, Holowiecki J, Polish Adult Leukemia Group.
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [Abstract] [Full Text] [Related]

  • 26. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ.
    J Clin Oncol; 2005 Aug 20; 23(24):5675-87. PubMed ID: 16110027
    [Abstract] [Full Text] [Related]

  • 27. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Polish Adult Leukemia Group.
    Ann Hematol; 2005 Sep 20; 84(9):557-64. PubMed ID: 15856358
    [Abstract] [Full Text] [Related]

  • 28. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.
    J Clin Oncol; 2008 Jan 10; 26(2):196-203. PubMed ID: 18182662
    [Abstract] [Full Text] [Related]

  • 29. [Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
    Yao YY, Zhu Q, Zou LF, Dou HJ, Chen YM, Tang Y, Hu JP.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun 10; 17(3):774-6. PubMed ID: 19549406
    [Abstract] [Full Text] [Related]

  • 30. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH.
    J Clin Oncol; 1997 Aug 10; 15(8):2780-5. PubMed ID: 9256119
    [Abstract] [Full Text] [Related]

  • 31. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M.
    Ann Hematol; 2004 Nov 10; 83(11):696-703. PubMed ID: 15322763
    [Abstract] [Full Text] [Related]

  • 32. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E.
    Cancer; 2006 Mar 01; 106(5):1099-109. PubMed ID: 16435387
    [Abstract] [Full Text] [Related]

  • 33. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
    Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ.
    Leuk Lymphoma; 1993 Mar 01; 9(4-5):343-50. PubMed ID: 8394169
    [Abstract] [Full Text] [Related]

  • 34. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
    Bolaños-Meade J, Guo C, Gojo I, Karp JE.
    Leuk Res; 2004 Jun 01; 28(6):571-7. PubMed ID: 15120933
    [Abstract] [Full Text] [Related]

  • 35. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
    Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E.
    Haematologica; 2002 Aug 01; 87(8):804-7. PubMed ID: 12161355
    [Abstract] [Full Text] [Related]

  • 36. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H.
    Clin Lymphoma Myeloma Leuk; 2012 Aug 01; 12(4):244-51. PubMed ID: 22534616
    [Abstract] [Full Text] [Related]

  • 37. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E.
    Cancer; 2003 Mar 01; 97(5):1234-41. PubMed ID: 12599230
    [Abstract] [Full Text] [Related]

  • 38. [Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].
    Qin TJ, Xu ZF, Wang JY, Zhou CL, Xiao ZJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct 01; 17(5):1342-6. PubMed ID: 19840480
    [Abstract] [Full Text] [Related]

  • 39. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB.
    Jpn J Clin Oncol; 2005 Oct 01; 35(10):612-6. PubMed ID: 16172175
    [Abstract] [Full Text] [Related]

  • 40. The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
    Pagano L, Mele L, Voso MT, Chiusolo P, Putzulu R, Mazzotta S, Leone G.
    Haematologica; 2001 Apr 01; 86(4):440-1. PubMed ID: 11325656
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.